Skip to content
AnalystLens

STRYKER CORP 8-K Report, Financial Results (Oct 29, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 29, 2024
Period End
October 29, 2024
Security
SYK
In the record · 2016–202610-K1110-Q328-K125

SYK filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 125 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Leadership change8-K · Dec ’19Dec ’19
  3. Material agreement8-K · Feb ’22Feb ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.

Stryker reported third quarter 2024 results on October 29, 2024 that were strong on both the top and bottom lines.

Reported net sales rose 11.9% to $5.5 billiona (11.5% organic, 12.0% constant currency), led by MedSurg and Neurotechnology at +12.7% organic and Orthopaedics and Spine at +9.7% organic. Organic growth was driven mainly by unit volume (10.3%), with a modest contribution from price (1.2%). Reported EPS grew 20.0% to $2.16, while adjusted EPS grew 16.7% to $2.87, and adjusted operating margin expanded 130 bps to 24.7%.

Part of the quarter's extra selling day and the acquisition contribution (0.5 points) also supported reported growth. Management raised its full-year 2024 outlook. Organic net sales growth is now guided to 9.5%–10.0% (up from prior expectations, with pricing contributing 0.5%–1.0%), and adjusted EPS guidance is $12.00b–$12.10.

Management noted that the expected FX impact (about $0.10c on EPS) is already reflected. Management also reiterated that it is on track for its adjusted operating margin expansion goals. Investors should keep an eye on the balance sheet and the quality of earnings.

Long-term debt rose to $13.3 billiond from $10.9 billion at year-end 2023, reflecting acquisition funding, and goodwill and intangibles climbed to $21.3 billion. Nine-month acquisition spending was $1.6 billion, and inventories increased to $5.3 billion.

Reported operating cash flow was $2.3 billion for the nine months, up modestly year over year, while the gap between reported and adjusted results remains significant, largely because of amortization of purchased intangibles and recurring structural optimization charges. The filing is furnished rather than filed under Item 2.02, and it contains forward-looking statements subject to risks including pricing pressure, FX, regulatory actions, recall-related costs and integration of acquisitions.

02—Key points

Key Highlights

  1. Reported net sales rose 11.9% to $5.49 billion; organic growth was 11.5%, with unit volume contributing 10.3 points and price 1.2 points.
  2. MedSurg and Neurotechnology sales grew 12.8% reported (12.7% organic) to $3.2 billion, led by Medical (+17.6% in the U.S.) and Endoscopy; Orthopaedics and Spine grew 10.7% reported (9.7% organic) to $2.3 billion, with Hips (+15.9%) a standout.
  3. Adjusted operating margin expanded 130 bps year over year to 24.7%; reported operating margin was 19.7%.
  4. Reported diluted EPS rose 20.0% to $2.16; adjusted diluted EPS rose 16.7% to $2.87, versus $2.46 a year earlier.
  5. Full-year 2024 guidance was raised: organic sales growth of 9.5%–10.0% (pricing +0.5%–1.0%) and adjusted diluted EPS of $12.00–$12.10, after an approximately $0.10 FX headwind.
  6. Balance sheet leverage increased: long-term debt rose to $13.3 billion (from $10.9 billion at YE 2023) and goodwill/intangibles reached $21.3 billion, reflecting acquisition funding of $1.6 billion year to date.
  7. Nine-month reported EPS was $6.35 (+20.5%) and adjusted EPS was $8.18 (+14.5%), with cash from operations of $2.3 billion and dividends paid of $914 million.

03—Questions

Frequently Asked Questions

  1. Why did Stryker raise its 2024 guidance?

    Management cited a strong first nine months, sustained demand for capital products, healthy procedure volumes and strong sales momentum entering the fourth quarter. The raised organic growth range of 9.5%–10.0% and adjusted EPS range of $12.00–$12.10 already incorporate the expected FX headwind of roughly $0.10 per share.

  2. How much of the growth came from price versus volume?

    Most of the growth was volume-driven. Organic growth of 11.5% included 10.3 points from unit volume and 1.2 points from higher prices. For the full year, management expects pricing of 0.5%–1.0%.

  3. Why is there a large gap between reported and adjusted EPS?

    Adjusted results exclude items such as amortization of purchased intangibles ($159 million in the quarter, about $0.32 per share), structural optimization and other special charges, acquisition and integration costs, medical device regulation compliance costs and tax matters. Reported EPS of $2.16 compares with adjusted EPS of $2.87, and the difference is recurring in nature for an acquisitive company.

  4. Is Stryker's balance sheet becoming more leveraged?

    Yes. Long-term debt, excluding current maturities, increased to $13.3 billion at September 30, 2024, from $10.9 billion at December 31, 2023, as the company borrowed to fund acquisitions. Shareholders' equity rose to $20.1 billion. Cash and short-term investments totaled about $4.6 billion at quarter end.

04—Continue

← View all 8-K filings